The next big thing in hair growth

Follicopeptide is the ingredient brand name for Coegin Pharma’s clinically proven peptide, FOL005. Specifically designed to enhance hair growth, this peptide offers a novel alternative to existing products. Hair growth product series containing Follicopeptideare expected to be commercially available by late 2025.

The next big thing in hair growth

Follicopeptide™ is the ingredient brand name for Coegin Pharma’s clinically proven peptide, FOL005. Specifically designed to enhance hair growth, this peptide offers a novel alternative to existing products. Hair growth product series containing Follicopeptide™ are expected to be commercially available by late 2025.

Follicopeptideis a peptide for enhancing hair growth

Follicopeptideis a peptide, a small protein, that is specifically designed to enhance hair growth. It has shown high safety and positive results in clinical studies with as high response rate as 70%.

The proprietary topical formulation is a non-running gel which is easy to apply. It is designed to penetrate the skin well and spread Follicopeptideevenly in both the skin and the hair follicles. The formulation keeps the peptide stable for several years at room temperature.

 Clinically proven efficacy,
more than 70% responders

 For both men and women

Application only once daily

Strong patent

This is how Follicopeptideworks

Follicopeptideis a unique and patented peptide based on a modified part of the endogenous human structural protein osteopontin. Osteopontin is a glycoprotein expressed by many tissues, among these also the hair follicle, bone and involved in inflammatory processes.

The most common form of hair loss is androgenetic alopecia. It develops slowly over time and is caused by the hair follicle becoming smaller and, in the end, it is ultimately inactive and is not able to grow new hair, a process called miniaturisation. A key driver for this is due to lack of blood flow to the muscle. Follicopeptiderevitalises the blood vessels, hence enhances hair growth.

Clinically validated

Clinical studies including more than 300 participants with androgenic alopecia demonstrated that Follicopeptide, applied once daily, resulted in remarkable growth of new hairs in individuals with a hair density of less than 255 hairs per square centimetre after just four months.

Want to be a part of this journey?

Interested in partnering up with us to bring Follicopeptide to the market? Please contact our CEO Jens Eriksson: je@coeginpharma.com

Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia. Coegin is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026.

Coegin Pharma’s shares are listed on NGM Nordic SME and Börse Stuttgart.

Website: coeginpharma.com/en

Women with long hair.
Female face with eye with long eyelashes.
Man with a full beard.
Female face with full eyebrow.